Global and United States Antiprotozoal Drugs Market Size, Status and Forecast 2021-2027

Antiprotozoal agents (ATC code: ATC P01) is a class of pharmaceuticals used in treatment of protozoan infection.
Antiprotozoals are used to treat protozoal infections, which include amebiasis, giardiasis, cryptosporidiosis, microsporidiosis, malaria, babesiosis, trypanosomiasis, Chagas disease, leishmaniasis, and toxoplasmosis.[5] Currently, many of the treatments for these infections are limited by their toxicity. Some antiprotozoal drugs include the antimalarials Aralen (chloroquine), Daraprim (pyrimethamine), Lariam (mefloquine) and Plaquenil (hydroxychloroquine); Flagyl (metronidazole) which is active against Entamoeba histolytica and Trichomonas vaginalis; and Mepron (atovaquone) for Pneumocystis carinii.

Market Analysis and Insights: Global Antiprotozoal Drugs Market
The global Antiprotozoal Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Antiprotozoal Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Antiprotozoal Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Antiprotozoal Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Antiprotozoal Drugs market.

Global Antiprotozoal Drugs Scope and Market Size
Antiprotozoal Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Antiprotozoal Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
by Diseases
Amoebic Dysentery
Antimalarial Drug
Leishmaniasis & Chagas Disease
by Drugs
Metronidazole
Atovaquone
Benznidazole
Dehydroemetine
Eflornithine
Emetine
Fenbendazole
Iodoquinol
Melarsoprol
Others (like Meglumine antimonite, Nifurtimox, Pentamidine, etc.)

Segment by Application
Hospital
Clinic

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Sanofi
Akthelia Pharmaceuticals Ltd
GlaxoSmithKline Plc
Immuron Ltd
Microbiotix Inc
Protein Potential LLC
Dr. Reddy’s Laboratories
Mission Pharmacal
Aceto Corp.
Mylan Pharmaceuticals
Impax Laboratories
Pfizer
Lupin Pharmaceuticals
Glenmark Pharmaceuticals
Sun Pharmaceutical
Heritage Pharmaceuticals
Gilead Sciences
Johnson & Johnson
Bristol-Myers Squibb
Profounda
Knight Therapeutics
Albert David
Wanlong
Fangsheng
KPC Pharmaceuticals
Guilin Pharmaceuticals
Pude Pharmaceutica